Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Your Article Summary
The ENDOTRIAL Study: A Spontaneous, Open-Label, Randomized, Multicenter, Crossover Study on the Efficacy of Sildenafil, Tadalafil, and Vardenafil in the Treatment of Erectile Dysfunction
The Journal of Sexual Medicine, 07/02/09
Jannini EA et al. - An overall equivalence was demonstrated in the subjective perception of treatment benefits for all the PDE5i tested. However, sildenafil, in a dose-dependent manner, was the unique PDE5i able to ameliorate some of the penile flow parameters within the 8-week treatment period. These findings should be interpreted conservatively because of the observational nature of the study.
Related Articles
Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction: A Clinical Practice Guideline From the American College of Physicians
Annals of Internal Medicine, 10/30/09
Relevance Score: 70%
Effects of 12-Month Tadalafil Therapy for Erectile Dysfunction on Couple Relationships: Results from the DETECT Study
The Journal of Sexual Medicine, 10/28/09
Relevance Score: 69%
Evaluation of Microalbuminuria in Patients with Erectile Dysfunction
The Journal of Sexual Medicine, 10/07/09
Relevance Score: 69%
New Drug Udenafil for Erectile Dysfunction in US Trials
Internet Source, 11/10/09
Relevance Score: 68%
The Association of Serum Prolidase Activity and Erectile Dysfunction
Journal of Andrology, 10/23/09
Relevance Score: 68%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial
Gastroenterology, 12/08/09
Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis
Gastroenterology, 12/08/09
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease
Clinical and Experimental Gastroenterology, 12/08/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


